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Innate and adaptive immune cells form an ongoing partnership during an immune response. In this issue of
Immunity, Oliphant et al. (2014) show that MHC class II-peptide presentation by group 2 innate lymphoid
cells is needed for reciprocal regulation of both cell types, resulting in effective antihelminth immunity.Many immunology students are taught
that the innate immune system acts as
our first rough-and-ready line of defense
against infection, before the more finely
honed adaptive B and T cell populations
take over. Implicit in this model is that
innate responses simply die out once
adaptive immunity kicks in, but little
consideration has been given to any
mechanistic pathways capable of check-
ing innate responsiveness.
Now, however, we are coming to
appreciate that there is an ongoing
innate-adaptive partnership in the im-
mune response and that neither arm
functions properly without the other.
Thus, innate populations can fulfill critical
roles, such as cytokine production, in the
mature immune response alongside the
adaptive cells. New data from Oliphant
et al. (2014) reveal that for a subset of
innate lymphoid cells (ILCs) and antigen-
specific CD4+ T cells, this cooperation
and reinforcement is mediated through
major histocompatibility complex (MHC)
class II interactions. This finding also
illuminates a pathway through which
continuing ILC activation is mediated,
or indeed terminated, in the absence of
appropriate peptide ligand or cognate
T cells (Figure 1).
Although the initial studies character-
izing cells that would become part of
the ILC family noted their expression of
MHC-II (Mebius et al., 1997, Neill et al.,
2010), what functional role this served
has been unclear. It is established that
induction of T cell responsiveness is
highly dependent on dendritic cells
(Hammad et al., 2010, Phythian-Adams
et al., 2010). Recently, it was demon-174 Immunity 41, August 21, 2014 ª2014 Elsstrated that expression of MHC-II by the
RAR-related orphan nuclear receptor g
(RORg)-expressing group 3 ILC (ILC3)
subset confers control of CD4+ T cell
responses to commensal bacteria (Hep-
worth et al., 2013) and that MHC-II-
expressing ILC2 could present peptide
to T cells in vitro (Mirchandani et al.,
2014). The latter authors also found that
exogenous interleukin-2 (IL-2) stimulated
cytokine production by ILC2s. Now,
Oliphant et al. bring together these find-
ings by showing that the stimuli ILC2s
require from the T cells are only delivered
upon recognition of cognate peptide pre-
sented by MHC-II. Such a mechanism
allows for the decay of ILC2 activation
once antigen from pathogens or other
target sources has fallen below an effec-
tive threshold.
Understanding the roles of ILCs in vivo,
within an intact immune system, has
been hampered by a lack of robust
mouse models. Oliphant et al. now report
on two elegant strategies to selectively
deplete ILCs in vivo. First, they target
the inducible T cell costimulator (ICOS)
locus to insert a diphtheria toxin receptor
(DTR) subunit that would allow timed
deletion of ICOS+ cells by administration
of diphtheria toxin (DT) in vivo. Because
ICOS expression is shared with many
T cells, the DTR-encoding gene is
flanked by Loxp sites that allow the insert
to be excised in cells expressing Cre, in
this case driven by the T cell-specific
Cd4 promoter. Hence, only ILCs will be
liable to DT-mediated elimination. Sec-
ond, the authors take advantage of the
essential requirement for the RORa tran-
scription factor in ILC development;evier Inc.because this plays many other critical
physiological roles, it is necessary to
delete the gene only in lymphoid cells,
which is accomplished by constructing
a Loxp3-flanked RORa transgene and
introducing Cre under the Il7r promoter
(in this instance the Rorafl allele is
paired with a functional knockout allele,
Staggerer, to maximize the efficiency
of deletion). Both systems showed a
dramatic reduction in CD4+ T cell type
2 responses, measured by IL-5 and
IL-13 production, and in expulsion of
the intestinal helminth Nippostrongylus
brasiliensis, indicating the need for innate
ILC2s in amplifying the adaptive type 2
response.
In considering potential mechanistic
interactions between ILC2s and T cells,
Oliphant et al. assessed MHC-II expres-
sion by ILC2s, which was expressed in
significantly lower and more heteroge-
nous amounts than on B cells, and
expression was lost following short-term
culture; the unusual plasticity of MHC-II
expression on ILCs does call into question
whether they constitute a dedicated
antigen-presenting cell. On the other
hand, many ILC2s also expressed CD80
and CD86, suggesting that they are able,
in the appropriate setting, to drive T cell
activation. This is in contrast to the
ILC3 subset, which lacks expression of
these costimulatory molecules, consis-
tent with a regulatory role in tolerizing
T cell responses (Hepworth et al., 2013).
The authors show that ILC2s, in the
absence of dendritic cells (DCs), will drive
proliferation of T cell receptor (TCR) trans-
genic T cells in vitro and that, furthermore
ILC2s can take up, process, and present
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Figure 1. The Continuing Interplay between ILC2s and CD4+ T Cells
The expression of MHC-II by ILC2s and their ability to endocytose and pro-
cess antigen (1) might allow them to present peptide to and activate naive
Th0 cells (2), possibly favoring differentiation to Th2 by low ligand density.
Once induced (by conventional DCs as well as ILC2s), Th2 cells subsequently
interact with ILC2s, inspecting their MHC-II cargo, which, if bound by the TCR,
gives a further activation signal to the ILC2s (3), including the release of IL-2
that ligates CD25, the high-affinity IL-2 receptor (4). These signals drive further
IL-13 production by ILC2s, orchestrating a suite of innate effector cells
such as mucus-producing goblet cells (5), as well as alternatively activated
macrophages (not shown) that promote expulsion of intestinal helminths.
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gous to professional APCs.
They also suggest that the
low MHC-II expression on
ILC2s might actually corre-
spond to the selective differ-
entiation of T helper 2 (Th2)
cells, in that reduced ligand
density and TCR engage-
ment is thought to predis-
pose in that direction (van
Panhuys et al., 2014). How-
ever, it would seem to be
early days in judging whether
ILC2s play any critical role
in antigen presentation or
are simply endowed with
the ability to top up the
T cell response when the
professionals are otherwise
engaged.
If ILC2s use MHC-II to pre-
sent antigen, what happens
when MHC-II-deficient ILC2s
are administered to mice
in vivo? The authors tested
this in a transfer system in
which recipient mice are IL-
13-deficient and thereby un-
able to expel N. brasiliensis.
When wild-type (MHC-II+IL-
13+) ILC2s are transferred,
parasites are expelled; how-
ever, if the ILC2s lack MHC-
II, the recipients fail to expel
despite a vigorous Th2
response due to endogenousMHC-II+ APCs. Thus, the tables are
turned and MHC interactions are required
to activate (or to maintain the activation
of) ILC2s for IL-13 production, clearly
demonstrating for the first time that
ILC2:CD4+ T cell crosstalk potentiates
the innate type 2 response.
In vitro cocultures established that
MHC-II antibody blockade affected not
only T cell activation but also the stimula-
tion of proliferation and cytokine pro-
duction by ILC2s. This result provides
confirmation that MHC-II acts as a
display on ILCs that allows T cell scrutiny
and regulation. But does this checkpoint
operate by ILCs being dependent
on a surface-mediated interaction with
T cells, or on soluble cytokines? Part of
the answer at least is through soluble
mediators, with the key cytokine respon-
sible shown to be IL-2, both in vitro
(modulating ILC2 expression of IL-13by adding or blocking IL-2) and in vivo
(in recombinase-activating-gene-deficient
mice in which limiting IL-2 is available
due to the absence of T cells). In the
latter model, the authors succeeded in
inducing worm expulsion by adding IL-2
to the ILCs, which otherwise cannot
achieve functional immunity.
However, this result implies that
whereas ILC2s present peptide to
T cells, which only produce IL-2 if there
is a cognate interaction with their TCR,
the IL-2 produced can activate all ILC2s
irrespective of their peptide loading.
Arithmetically, this might be an efficient
mechanism at a time point at which the
antigen-specific Th2 cells have greatly
expanded (so that there are plenty of
cognate T cells whose job it is to produce
IL-2) and a relatively small pool of ILC2s
are recruited to the maximum possible
extent, regardless of whether they haveImmunity 41, August 21taken up a particular antigen.
It will be interesting to observe
whether further mechanisms
of crosstalk between ILC2s
and T cells are identified,
perhaps through cell-surface
receptor-ligand interactions.
For theMHC-II+ ILC3s at least,
the expression of a distinct set
of costimulatory molecules
suggests that additional ILC:T
cell interactions influence the
response (Kim et al., 2003).
What are the broader impli-
cations of these findings?
Oliphant et al. have developed
refined mouse models that
will enable the dissection of
ILC2 function in vivo, particu-
larly the contribution of these
cells to adaptive immune re-
sponses. There is now a stron-
ger emphasis placed on ILC2s
as the source of functional
IL-13 in the longer term during
an immune response, but the
ongoing production of this
cytokine is dependent on
approval by CD4+ T cells,
as if the adaptive immune
system is simply outsourcing
the heavy lifting to a less
sophisticated population. The
studies have tested function-
ality in the helminth system
of N. brasiliensis, which is a
relatively soft target in beingreadily expelled by immunosufficient
mice: it might be interesting to test the
ability of IL-2-driven ILC2s to act autono-
mously in a more challenging infection
such as Schistosoma mansoni or Heli-
gmosomoides polygyrus and even more
interesting to evaluate their contribution
in allergic models such as asthma-like
inflammation of the airways. Notably,
ILC2s in secondary lymphoid tissue ex-
press higher amounts of MHCII than in
tissues such as the lung and gut (Hep-
worth et al., 2013), perhaps indicating
activation states for ILC2s. Identification
of how MHC-II is regulated on ILCs
appears to be a key question for the
future. If ILC2s, spurred on by continual
dialog with T cells, are responsible for
the longer-term exacerbation and disease
in the asthma setting, they will present
a vital target for novel therapies yet to be
developed., 2014 ª2014 Elsevier Inc. 175
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Disease tolerance describes the ability of an infected host to limit disease severity without negatively impact-
ing the causative pathogen. Bessede et al. (2014) show that the aryl hydrocarbon receptor is an essential
component of disease tolerance during bacterial infection in mice.The pathologic outcome of infection is
revealed by the appearance of clinical
symptoms, reflecting a more or less pro-
nounced dysfunction of homeostasis
in the infected host. Depending on the
severity of disease, host reproductive
capacity and survival—fitness—might
eventually be compromised as well. It
follows that host defense strategies
against infection should share as a
common endeavor the preservation of
homeostasis and fitness. The prevailing
strategy to achieve this goal is to eliminate
the causative agent of disease, i.e., the
pathogen, via immune-driven resistance
mechanisms (Figure 1).
Host resistance mechanisms rely on
the recognition of pathogens by germ-
line-encoded pattern recognition recep-
tors (PRR), activating the host innate
immune system, which targets patho-
gens for destruction and/or expulsion
(Figure 1). Activation of adaptive immu-
nity provides a more specific, robust,
and long-lasting protection mechanism
against infection. Enhancing immune-
driven resistance mechanisms, e.g.,
through vaccination, has proven to be
an extremely efficient therapeutic strat-
egy against infectious diseases, relievingmankind from the evolutionary con-
straints imposed by many pathogens.
Presumably for this reason, we came
to consider immune-driven resistance
mechanisms as the only defense strategy
that really matters when taking into
consideration protection against infec-
tious diseases. Reality, however, is prob-
ably more complex.
The study by Bessede et al. (2014)
highlights the ‘‘relative cost’’ associated
with immune-driven resistance mecha-
nisms, as these become pathologic
and contribute to disease severity, i.e.,
immunopathology (Figure 1). Bessede
et al. (2014) show that this evolutionary
trade-off is reduced via an immunoregu-
latory mechanism involving a stress-
response pathway controlled by the aryl
hydrocarbon receptor (AhR) and con-
ferring disease tolerance to infection
(Figure 1).
Disease tolerance is a concept that
stems from observations made originally
in the context of infection in plants and
revealing that these can ‘‘tolerate’’ patho-
gens via a defense strategy that does not
appear to reduce their pathogen load but
instead limits the extent of tissue damage
associated with infection (Schaefer,1971). This defense strategy, coined as
tolerance, remained in the literature for
more than a century, as a specificity of
host-pathogen interactions in plants
(Schaefer, 1971). As it turns out, however,
tolerance is an evolutionary conserved
host defense strategy against infection
that is shared by plants and animals,
including insects, worms, mice, and
most likely humans as well (Medzhitov
et al., 2012). Disease tolerance is the
term used to describe the same concept
defined originally in the plant literature
and referring to preservation of host
fitness during infection, without con-
comitant reduction of pathogen load
(Medzhitov et al., 2012). The mechanisms
underlying disease tolerance in mammals
remain poorly understood, being linked so
far to stress-responsive pathways that
limit the extent of tissue damage caused
directly by pathogens or indirectly by
host immune-mediated resistance mech-
anisms (Figure 1; Figueiredo et al., 2013;
Jamieson et al., 2013; Larsen et al.,
2010). Bessede et al. (2014) propose
that the stress-response pathway regu-
lated by AhR is critically involved in
promoting disease tolerance to bacterial
infections in mice.
